BMS confirms job cuts at investor meeting

Share this article:

Bristol-Myers Squibb confirmed on Wednesday that it would cut nearly 10% of its 43,000-member workforce. The drugmaker also announced plans to sell or close half of its 27 manufacturing plants across the globe, outsource some of its manufacturing and shrink its portfolio of 500 products by 60%.

Last week, 1,300 BMS employees were notified they would be losing their jobs. An additional 3,500 employees will be let go in 2008, under the overhaul that the company says will reduce expenses by $1.5 billion by 2010.

The drugmaker declined to say exactly where the layoffs would occur, other than an unspecified number had been notified at a biotechnology plant in East Syracuse, NY. Many of the 1,300 jobs already eliminated are in administrative positions like human resources, information technology and finance, the company said.

"It is difficult to see our valued colleagues leave the company, but right-sizing our workforce across all areas is critical to achieving our productivity goals and enhancing the competitive position of the company,” said BMS CEO James Cornelius in a statement. “While we are reducing headcount in certain functions, we will continue to invest in R&D, biologics and commercialization talent."

BMS has already announced it would be closing manufacturing plants in Colon, Panama, Mayguez, Puerto Rico and Barcelona, Spain.
And the company might also sell its baby formula business, Mead Johnson Nutritionals and its wound care products business, ConvaTec, which could fetch a price of about $13 billion, according to analysts.

Following its overhaul, BMS is expected to maintain only one floor at its Park Avenue, New York headquarters where it occupied 550,000 square feet as recently as 10 years ago. The company has been based in Manhattan since the 1940s.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...